AbbVie Inc. (ABBV) Falls 6.87% for February 05

Equities Staff  |

One of the S&P 500’s big losers for Friday February 05 was AbbVie Inc. (ABBV). The company’s stock fell 6.87% to $52.86 on volume of 9.57 million shares.

The stock opened the day at 56.25 and traded between a low of $52.85 and a high of $56.34. The stock finished the day down $3.9 per share. AbbVie Inc. has an average daily volume of 9.88 million and a total float of 1.63 billion shares. The 50-day SMA for AbbVie Inc. is $56.64 and its 200-day SMA is $60.96. The high for the stock over the last 52 weeks is $71.60 and the low is $45.45.

AbbVie Inc is a research-based biopharmaceutical company. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications.

AbbVie Inc. is centered in North Chicago, IL, and has 28,000 employees. Today’s trading day leaves the company with a market cap of $86.41 billion. The company has a P/S ratio of n/a, P/B ratio of 17.8, and a -10.9.

For a complete fundamental analysis analysis of AbbVie Inc., check out’s Stock Valuation Analysis report for ABBV. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:



Symbol Last Price Change % Change










Q BioMed CEO provides a Corporate Update

Denis Corin, CEO of Q BioMed Inc. ”Q“, a biomedical acceleration and development company, focused on licensing and acquiring undervalued biomedical assets in the healthcare sector, provides a corporate update.

Emerging Growth

Lomiko Metals Inc.

Lomiko Metals Inc is an exploration stage company. It is engaged in the acquisition, exploration and development of resource properties. Its projects include Vines Lake project and Quatre - Milles…